SpeeDx and Roche Partner to Expand Access to Antibiotic Resistance Tests

SpeeDx has partnered with Roche, a global pioneer in pharmaceuticals and diagnostics, to expand access to infectious disease and antibiotic resistance tests and technology. Under the terms of the agreement, Roche will have non-exclusive access to SpeeDx existing tests and technology for the management of antibiotic resistance in STIs, to quickly bring new products to a broader group of patients around the world.

“The agreement with SpeeDx will allow Roche Diagnostics to provide clinicians with important new tools for detecting antibiotic resistance in patients with sexually transmitted infections.” said Mario Torres, Head of Roche Molecular Diagnostics.

Read the full press release.